Related references
Note: Only part of the references are listed.O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction
Marta Brell et al.
BMC CANCER (2011)
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
Lucie Karayan-Tapon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients
M. Schaich et al.
ANNALS OF ONCOLOGY (2009)
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J. Dunn et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic Impact of O6-Methylguanine-DNA Methyltransferase Silencing in Patients With Recurrent Glioblastoma Multiforme Who Undergo Surgery and Carmustine Wafer Implantation A Prospective Patient Cohort
Philippe Metellus et al.
CANCER (2009)
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2009)
Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
Martin Glas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer L. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Jennifer A. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study
Izabela Zawlik et al.
NEUROEPIDEMIOLOGY (2009)
MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
E. R. Gerstner et al.
NEUROLOGY (2009)
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin
Chul-Kee Park et al.
NEUROPATHOLOGY (2009)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Thierry Gorlia et al.
LANCET ONCOLOGY (2008)
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival
Marica Eoli et al.
CLINICAL CANCER RESEARCH (2007)
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
M Esteller
BRITISH JOURNAL OF CANCER (2006)
Meta-analysis when only the median survival times are known: A comparison with individual patient data results
S Michiels et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2005)
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
M Brell et al.
CLINICAL CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
O6-Methylguanine-DNA Methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course
T Watanabe et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-primidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy
T Kamiryo et al.
NEUROSURGERY (2004)
Generating mutations but providing chemosensitivity:: the role of O6-methylguanine DNA methyltransferase in human cancer
M Esteller et al.
ONCOGENE (2004)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: What you don't see you can't get!
L Duchateau et al.
BIOMETRICS (2000)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
